ADPT — Adaptive Biotechnologies Cashflow Statement
0.000.00%
Last trade - 00:00
- $679.85m
- $519.88m
- $170.28m
- 42
- 18
- 74
- 42
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -68.6 | -146 | -207 | -200 | -225 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 11.3 | 28.9 | 57.4 | 67 | 92.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 255 | -40.8 | -56.8 | -71.5 | -46.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 205 | -150 | -193 | -184 | -156 |
Capital Expenditures | -11.2 | -18.8 | -61.7 | -16.3 | -10.7 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -470 | -98.2 | 243 | 19.3 | 140 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -482 | -117 | 181 | 2.9 | 130 |
Financing Cash Flow Items | -4.99 | -0.321 | 0.429 | 124 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 320 | 294 | 27.1 | 132 | 2.25 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 43.6 | 26.9 | 15.6 | -48.8 | -24.4 |